Despite decades of therapeutic advances, myocardial infarction remains a leading cause of death worldwide. Recent studies have identified HDLs (high-density lipoproteins) as a potential candidate for mitigating coronary ischemia/ reperfusion injury via a broad spectrum of signaling pathways. HDL ligands, such as S1P (sphingosine-1-phosphate), Apo (apolipoprotein) A-I, clusterin, and miRNA, may influence the opening of the mitochondrial channel, insulin sensitivity, and production of vascular autacoids, such as NO, prostacyclin, and endothelin-1. In parallel, antioxidant activity and sequestration of oxidized molecules provided by HDL can attenuate the oxidative stress that triggers ischemia/reperfusion. Nevertheless, during myocardial infarction, oxidation and the capture of oxidized and proinflammatory molecules generate large phenotypic and functional changes in HDL, potentially limiting its beneficial properties. In this review, new findings from cellular and animal models, as well as from clinical studies, will be discussed to describe the cardioprotective benefits of HDL on myocardial infarction. Furthermore, mechanisms by which HDL modulates cardiac function and potential strategies to mitigate postmyocardial infarction risk damage by HDL will be detailed throughout the review.
arly reperfusion remains a pivotal measure to reduce mortality from myocardial infarction (MI). Nevertheless, coronary reperfusion inexorably leads to mechanisms of cell injury directed toward the originally affected ischemic tissue, that is, ischemia/reperfusion (I/R) injury. In fact, reperfusion injury is responsible for ≤50% of the acute cardiomyocyte damage during an acute coronary event and, as such, plays an important role in determining morbidity and mortality. 1 Recent data involving animal models ex vivo and in vivo have highlighted a possible role for HDLs (highdensity lipoproteins) in mitigating cardiac I/R. 2, 3 The potential benefit in restricting damage from I/R has motivated an extensive line of research to investigate possible therapeutic strategies involving HDL for acute coronary syndrome patients. However, the major challenge in pinpointing the exact role and therapeutic potential for HDL in MI lies in the fact that the acute inflammatory/oxidative response triggered for tissue repair may at the same time induce dysfunction of the HDL system. 4 Accordingly, we found that the acute phase response after MI induces changes in HDL structure, composition, function, and consequently transforms HDL into a dysfunctional proinflammatory particle 5 that may adversely influence the cardiovascular outcome. 6, 7 In a recent study, we found in an ex vivo murine model that myocardial reperfusion with healthy HDL reduces the mass of MI but the same does not occur when we reperfuse with HDL from patients in the acute phase of MI. 4 In patients with MI, we found a direct association between plasma HDL levels and the extent of MI as estimated by both nuclear magnetic resonance imaging and biochemical markers of myocardial tissue necro-sis in patients undergoing early coronary reperfusion. 4 No association was found in patients who did not have coronary reperfusion or with late reperfusion (>4 hours), indicating a possible connection to mechanisms of I/R injury. Myocardial reperfusion and the biochemical characteristics of the HDL may, therefore, play a key role in directing the outcome of the interaction between HDL and MI. This review is intended to discuss the multifaceted interaction between HDL and MI in its potential implications in the development of new MI therapies.
CHANGES IN HDL COMPOSITION AND FUNCTION DURING MI
During the first days after MI, plasma HDL cholesterol (HDL-C) declines and then rises progressively over weeks. 8, 9 The reduction in HDL-C results both from a decrease in the number of HDL particles and in its ester and free cholesterol content. Because of the decrease in LCAT (lecithin-cholesterol acyltransferase) activity during MI, the decrease in cholesteryl ester content is greater than that of free cholesterol. 5, 10, 11 In general, there have been reports of both increase and decrease in HDL triglyceride and phospholipid content, 12, 13 but the clinical significance of these findings remains unclear. Among the various phospholipid species carried by HDL, S1P (sphingosine-1-phosphate) deserves special attention. Total plasma S1P levels rise in the first 12 hours after MI contributing to the activation of local and systemic inflammatory response. 14, 15 Alternatively, S1P can bind to HDL, which can attenuate and even modify its effects. 15 Hence, the enrichment of HDL with S1P during MI may constitute a strategy to mitigate the inflammatory burst. 15 The HDL proteome, which consists of over 50 associated proteins, 16, 17 can also change with inflammation. Changes in the number, conformation, and electrical charge of Apo (apolipoprotein) A-I-the main protein on HDL-may also occur and influence HDL function, 18 such as its interaction with various receptors, enzymes, and transporters. 19 
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Metabolic and inflammatory processes are the main drivers for the change in HDL protein composition by favoring the exchange of protective proteins like Apo A-I, Apo A-IV, transthyretin, or RBP (retinol-binding protein) with proinflammatory proteins, such as SAA (serum amyloid A), complement 3, and LBP (lipopolysaccharidebinding protein). 20 These proinflammatory changes can profoundly alter HDL function and may even transform HDL from a protective particle into a pathogenic one. Proinflammatory settings can lead to an increase in SAA (≤10×), LBP, and complement system proteins. Indeed, during the first week after MI, SAA may turn into the major protein component of HDL. 17 Macrophages from damaged myocardial tissue produce IL (interleukin)-1 and IL-6, which synergistically induce the production of SAA in hepatocytes. 21 Free SAA in the bloodstream acts as a proinflammatory and prothrombotic mediator by activating NF-κB (nuclear factor-κB) in endothelial cells, 22 which can potentially increase MI size. SAA enrichment creates a predominant population of particles with HDL3 density, with a larger radius than expected for this HDL subclass. 12 Bound to HDL, the proinflammatory action of SAA is attenuated as that for S1P when it is bound to HDL. 22, 23 The drawback for such an interaction is the decline in HDL function. Because SAA enrichment occurs in exchange for Apo A-I, there is a corresponding decline in Apo A-I-related functions, such as antioxidant activity and cholesterol efflux capacity (CEC).
SAA binding-related dysfunction of HDL remains insufficiently explored to fully understand the side effect of this protein scavenging function. Clinical studies, using HDL SAA enrichment induced by endotoxin injection, have reported both decrease 24 and increase 25 of the CEC, revealing the complexity of this issue and the need of deeper appraisal. The capacity of HDL to inhibit endothelial cell inflammation, as assessed by secretion of adhesion molecules, seems, however, to be unaffected after SAA enrichment. 26 Other changes in protein composition of HDL after MI were identified through proteomic and gene ontology analysis. For instance, Apo A-II and, consequently, the particles containing both Apo A-I and Apo A-II (LpAI:AII) decline after 48 hours of the coronary event, particularly in patients with a high inflammatory response. 27 In contrast, Apo C-III content in HDL is increased after MI and stimulates proapoptotic signaling by phosphorylation of p38-MAPK (mitogen-activated protein kinase) and upregulation of the endothelial expression of a truncated form of Bid-a member of proapoptosis regulator proteins. 28 Clusterin or Apo J is an ATP-independent stress-activated chaperone that is normally carried in plasma by HDL and plays an important role in the inhibition of cell death pathways and in the modulation of prosurvival signaling and transcription networks. 29 In an ex vivo animal model of MI, coronary reperfusion with clusterin reduced the infarcted mass by 75%, indicating the potential relevance of its antiapoptotic effect in MI. 30 In observational studies in MI patients, the clusterin content of HDL decreases while Apo C-III content increases, thus causing an imbalance in favor of increased myocardial apoptosis particularly in the peri-infarction zone. 28 A summary of these HDL phenotypes and functional changes during MI is displayed in Table 1 .
HDL AND S1P
S1P is synthesized by the phosphorylation of the cell membrane-derived sphingosine through SphK1 (sphingosine kinase 1) and SphK2 (sphingosine kinase 2). Once synthesized, S1P rapidly reaches high plasma concentrations and, because of its amphipathic nature, is either bound to albumin (35%) or HDL (65%). 31 The hydrophobic α-helices of Apo M that is anchored to HDL phospholipid monomolecular layers are the main binding sites for S1P in HDL. 32 In fact, in Apo M-deficient mice, which practically do not contain S1P, loading of HDL with S1P completely corrected the ERK (extracellular-regulated kinase) 1/2 signaling defect. 33 A recombinant soluble non-HDL-related Apo M is capable of carrying S1P and activating S1P receptors on endothelial cells and attenuates I/R. 34 Taken together, it is conceivable that Apo M has a role in facilitating the transport of S1P by HDL but not that of activating signaling pathways related to I/R. S1P-driven signaling occurs through 5 G-proteincoupled receptor families (S1P1-S1P5). 35 S1P1 is the most expressed receptor in cardiomyocytes and normal endothelium, but there is also expression of S1P3 and S1P5 in these cells. 36 By contrast, dysfunctional endothelium is characterized by enhanced expression of S1P2. 37 The pharmacological blockade of S1P1 and S1P3 receptors triggers a marked increase in infarct mass. 38 However, the receptors may have a redundant action, since the single deletion of any one receptor did not increase the damage caused by the I/R injury. 39 SphK1 activity is increased in the cardiomyocyte after ischemic postconditioning, which suggests that S1P secretion may have a role on myocardial I/R injury. 40 Consistently, in SphK1 gene null mouse hearts, there is increased myocardial damage after I/R injury, and this genetic deletion attenuates the postconditioning effect. 41 Similar results in relation to the role of the SphK1 isoform in the generation of S1P and consequent protection from I/R injury were demonstrated in the Langendorff apparatus of wild-type and SphK1-null mouse hearts. 42 In in vivo murine models, S1P cell membrane receptors have been shown to play an important role in mediating the cardioprotection of the I/R injury, 43 and administration of S1P, S1P mimetic FTY720, 44, 45 and S1P-rich HDL reduces infarct size. 46 Thus, S1P carrier function of HDL may be critical in myocardial protection. Interestingly, intracellularly originated S1P may have an opposite adverse role, during I/R injury activating NF-κB ( Figure 1 ). Recently, it was demonstrated that S1P was the missing cofactor mediating the K63-linked polyubiquitination of RIP1 (receptoractivating protein 1) and the consequent activation of the IKK (inhibitor of nuclear factor kappa-B kinase)/ NF-κB cascade. 47 The role of HDL/S1P signaling in the cardiomyocyte and in ischemic heart disease is only partially understood ( Figure 1) . One of the proposed mechanisms is the eNOS (endothelial NO synthase)-dependent arterial vasodilatation through the S1P1 or S1P3 receptor in the coronary microcirculation. 48, 49 There was also decreased leukocyte recruitment in the infarcted area that seems to be related to the increased NO production-the blockade of NO synthesis by L-NAME (N ω -nitro-Larginine methyl ester) favored leukocyte recruitment. 46 HDL-bound S1P limits vascular inflammation in endothelial cells also by inhibiting phosphorylation of the p65 NF-κB subunit, thus suppressing TNF (tumor necrosis factor)-α-mediated VCAM-1 (vascular adhesion molecule 1) and ICAM-1 (intercellular adhesion molecule 1) release, and decreased leukocyte adhesion to endothelium was observed in mice with elevated S1P levels 50 (Figure 1 ). This type of cellular response appears to be dependent on a chaperone because, in contrast to HDL/S1P, albumin/S1P does not trigger this signaling. These anti-inflammatory effects of HDL/ S1P occur partially through the interaction of S1P1 with β-arrestin 2, 51 which negatively regulates NF-κB by direct binding and stabilizing IκB ( Figure 1 ). 52 HDL/ S1P also limits endothelial inflammation through PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase)/AKT (serine/threonine kinase 1)/eNOS signaling, enhancing endothelial barrier, decreasing apoptosis, and counteracting TNF inflammatory signaling. 53, 54 Lastly, HDL/ S1P inhibits macrophage apoptosis through JAK (janus kinase) 2/STAT3 (signal transducer and activator of transcription 3) and by inducing survivin expression, which may be an early protective event because macrophage activation is critically involved in myocardial tissue repairing after infarction. 55 
HDL AND OXIDATIVE STRESS DURING MI
The antioxidant capacity of HDL is typically lower in individuals with coronary artery disease than in healthy individuals. 56 After MI, this protective function of HDL undergoes an additional decline that reaches nadir on Apo indicates apolipoprotein; HDL, high-density lipoprotein; IL, interleukin; LBP, lipopolysaccharide-binding protein; LCAT, lecithin-cholesterol acyltransferase; MAPK, mitogen-activated protein; MI, myocardial infarction; NF-κB, nuclear factor-κB; RBP, retinol-binding protein; S1P, sphingosine-1-phosphate; and SAA, serum amyloid A kinase.
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the fifth day and is recovered by day 30. 5 In those MI patients with the most intense reduction of HDL antioxidant capacity, the greater the mortality in 30 days and in 4 years. 6 Consistently, the activity of PON1 (paraoxonase/arylesterase 1), which represents a major antioxidant enzyme of HDL, is reduced, during the acute Macrophage apoptosis is a critical, early event in the atherosclerosis progression. HDL/S1P, specifically, not Apo (apolipoprotein) A-I or HDL deprived of S1P, inhibits macrophage apoptosis through JAK (janus kinase) 2/STAT3 (signal transducer and activator of transcription 3) and survivin expression. In the cardiomyocytes, HDL/S1P binds to S1P2 triggering ERK (extracellular signal-regulated kinase) pathway to induce mitochondrial STAT3 to decrease mitochondrial permeability transition pore (MPTP) opening and subsequent mitochondria-induced apoptosis. Similarly, HDL/S1P activates Akt (serine/threonine kinase 1)/NO pathway and inactivates GSK (inosine/guanosine kinase) 3β via S1P1 and S1P3 receptors, which culminates in cardioprotection against IR. HDL/S1P also can promote phosphorylation of Cx43 (connexin 43) through PKC (protein kinase C), which also plays a central cardioprotective role in decreasing cell death. Another alternative protective pathway against IR is the survivor activating factor enhancement (SAFE) pathway, which involves TNF (tumor necrosis factor) and STAT3. HDL/S1P can activate the SAFE pathway via S1PR/JAK/STAT3 or through a crosstalk with TNF released by cardiomyocyte following ischemic preconditioning and postconditioning, which triggers the cascade TNFR2 (TNF receptor 2)/TRAF2 (TNF receptor associated factor 2)/SK1/S1P, the latter, a curious downstream target capable to induce STAT3. In endothelial cells, HDL/S1P induces eNOS (endothelial NO synthase) pathway to release NO via S1P1/3-Akt or ERK. Curiously, HDL also induces COX-2 (cyclooxygenase 2) expression in human umbilical venous endothelial cells, contributing to its cardioprotective action, through PKC and Sphk2. Additionally, HDL-bound S1P attenuates inflammatory response in vascular endothelial cells by enhancing the S1P1-β-arrestin 2 to suppress NF-κB (nuclear factor-κB)-dependent inflammatory pathways. cyt C indicates cytochrome C; ETC, electron transport chain; I/R, ischemia/reperfusion; MAPK, mitogen-activated protein kinase; Pak1-p, phosphorylated serine/ threonine-protein kinase; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; SK1, sphingosine kinase 1; and Sphk1, sphingosine kinase 1.
Downloaded from http://ahajournals.org by on April 2, 2020 phase of MI, and its reduction is inversely associated with the risk of recurrent coronary events even after adjustment for traditional risk factors and plasma concentration of HDL. 57, 58 During coronary reperfusion, cardiomyocytes, endothelial cells, and neutrophils that are present in the infarcted tissue generate reactive oxygen species and reactive nitrogen species. 59 The triggering of I/R injury by reactive oxygen species and reactive nitrogen species is among the deleterious effects of this oxidative stress. HDL is among the most potent antioxidant agents because of the combined actions of Apo A-I, E, A-II, A-IV, clusterin, and enzymes such as PON1, PAF-AH (platelet activation factor acetylhydrolase), LCAT, and GPSx (glutathione selenoperoxidase). 60 The synergist interaction of the various antioxidant proteins within HDL may be one of the key elements in its antioxidant capacity. For example, the binding of PON1 to the hydrophobic N terminus of Apo A-I favor the activity of this enzyme. [61] [62] [63] [64] Furthermore, the oxidized phospholipids sequestered and bound to Apo A-I can be hydrolyzed by PON1. [65] [66] [67] [68] The activity of PON1 is reduced in patients with cardiovascular risk factors or stable coronary disease, and this decrease is intensified in the first 48 hours after MI. 57, 69, 70 The extent to which HDL sequesters oxidized lipids, reactive oxygen species, and reactive nitrogen species, during this time, may then adversely affect HDL function, particularly its antioxidant activity 5, 57, 71 In addition, HDL absorbs oxidized molecules free or bound to other lipoproteins, such as LDLs (low-density lipoproteins), thereby reducing the overall proinflammatory stimulus. Indeed, the content of oxidized molecules in HDL particles increases from admission to the fifth day after MI and persists in elevated concentrations for at least 30 days. 10 This mechanism of antioxidant action of HDL, absorption of oxidized molecules, however, seems to have a limited capacity. In line with this concept, in post-MI patients, we found that there is a retention of oxidative stress products gathered into HDL that is inversely related to endothelial function. 10 We also found that, in contrast to healthy HDL, HDL obtained from post-MI patients does not protect myocardial tissue from I/R injury. 4 Indeed, in these patients manifesting MI, the plasma HDL concentration is positively related to the extent of MI. 4 The activity of CETP (cholesteryl ester transfer protein) may also have a role in the remodeling and performance of HDL as an antioxidant during MI. Enhanced CETP activity is associated with small HDL subclasses that are enriched in PON1, PAF-AH, and Apo A-IV. 61, 72, 73 In patients with MI and high CETP activity, the generation of oxidized HDL is significantly boosted, and this might be due to the transfer of oxidized lipids from Apo Bcontaining lipoproteins onto HDL. 74 Despite this favorable effect on the antioxidant capacity of HDL, we found that MI patients with enhanced CETP activity have a higher incidence of endothelial dysfunction and an increased recurrence of coronary events. 10 Taking together, it is plausible that exposure of HDL to reactive oxygen species and reactive nitrogen species generated during MI not only extinguishes the antioxidant reserve but also produces proatherogenic forms of HDL. In line with this, we observed that endothelial function assessed 15 days after MI is inversely proportional to the plasma levels of oxidized HDL. 5 From a mechanistic point of view, oxidized HDL can activate LOX-1 (lectin-like oxidized LDL receptor 1) in the endothelial cells triggering PKC (protein kinase C) βII and inhibiting eNOS activation and NO production ( Figure 2 ). 57 Activation of MPO (myeloperoxidase)-a protein expressed at high levels by inflammatory macrophages in MI site and atherosclerotic lesions-may also lead to dysfunctional HDL during MI. MPO uses H 2 O 2 and chloride ion to produce hypochlorous acid that, in turn, converts Apo A-I tyrosine-192 into 3-chlorotyrosine and methionine-148 into sulfoxide methionine. 71, 75, 76 These site-specific changes inhibit Apo A-I binding, diminishing LCAT activation and CEC mediated by ABCA1 (ATP-binding cassette transporter A1). 71 In a seminal study, Peng et al 77 demonstrated that tryptophan-Apo A-I residues are essential elements to Apo A-I function and are susceptible to oxidation. Oxidation of 4 tryptophan residues leads to loss of function, but substitution of tryptophan with phenylalanine maintained the complete function of Apo A-I and conferred resistance to oxidative inactivation. 77 As the risk factors that favor the manifestation of MI also reduce the antioxidant capacity of HDL, the antioxidant action of native HDL is probably insufficient in these patients. Based on these findings, the development of Apo A-I mimetics or reconstituted HDL (rHDL) that are designed to be resistant to MI-induced dysfunctional oxidation would represent a potential therapeutic strategy.
HDL AND CHOLESTEROL EFFLUX FROM CELLS
During acute coronary syndromes, HDL-mediated CEC is reduced, 57,78 regardless of HDL plasma levels. This decline in CEC is less intense in individuals with non-ST-segment-elevation MI or unstable angina when compared with ST-segment-elevation MI. 78 The greater myocardial necrosis/apoptosis mass and higher inflammatory activity in ST-segment-elevation MI may account for decreased CEC in acute coronary syndrome patients.
The pathway of cell cholesterol efflux that seems to be most affected by MI is the one mediated by ABCA1, 70 which can reduce HDL-mediated CEC by way of specific oxidative changes mediated by MPO in tyrosine-192 and methionine-148 residues of Apo A-I. 71 Such attenuation in CEC occurs in different HDL subspecies of STsegment-elevation MI patients, 13 which suggests that Apo A-I has a central role in this process. In parallel, Apo A-I/ABCA1-mediated cholesterol efflux reduces the expression of proinflammatory cytokines in macrophages, indicating that the association between CEC and inflammation may be bidirectional. 79 A recent study with 1609 MI patients treated with primary angioplasty demonstrated that the CEC measured in the acute phase of the coronary event was inversely associated with all-cause mortality at a mean follow-up of 1.9 years, regardless of the level of HDL-C. 80 As the administration of rHDL (CSL112) in such MI patients improved CEC, 81 the utilization of rHDL was proposed as a possible therapy for MI. The AEGIS-II (ApoA-I Event Reducing in Ischemic Syndromes II; http://www. clinicaltrials.gov, unique identifier: NCT03473223) was, therefore, designed as a randomized, placebo-controlled, multicenter, double-blind, phase 3 trial of ≈17 000 patients with MI to test this hypothesis. The study has a limitation in that the amount of HDL infused in these patients (6 g of Apo A-I) is relatively small compared with the total plasma pool of Apo A-I (20 g). In addition, patients will be enrolled within 7 days after MI when the opportunity to mitigate the I/R injury no longer exists.
HDL AND GLUCOSE HOMEOSTASIS
An abrupt decline in insulin sensitivity (IS) during the first few hours of MI occurs in about half of patients. 82 The great relevance of this fact comes from increased mortality at 30 days, 1 year, and ≤20 years in those who present with stress hyperglycemia, regardless of diabetes mellitus. [82] [83] [84] Stress dysglycemia may affect clinical outcome by favoring oxidative stress, systemic inflammatory activity, cardiomyocyte apoptosis, thrombogenesis, and endothelial dysfunction. It can also hinder collateral circulation development and ischemic preconditioning. 85, 86 In mice, rHDL delivered during reperfusion increases myocardial glucose uptake and oxidation, reduces left ventricular infarct size, and increases capillary density and postischemic left ventricular function. 87 From a mechanistic viewpoint, cell model studies indicate that HDL increases IS via stimulation of the AMPK (AMP-activated protein kinase) pathway in muscle 88, 89 and adipose tissues. 90 Furthermore, Apo A-I promotes the phosphorylation of AMPK and ACC (acetyl-coenzyme A carboxylase), hence increasing IS. 89 HDL/Apo A-I binds to ABCA1 and triggers calcium influx, which activates CAMKK (calcium/calmod-
Figure 2. Endothelial effect of HDL (high-density lipoprotein) from healthy (A) or ST-segment-elevation myocardial infarction (STEMI) individuals (B).
This scheme shows the change in HDL composition after acute myocardial ischemia and its effects on the endothelium. Endothelial cells possess NO-mediated protective vasodilation functions, which could be regulated by the interaction of blood components with the wall vessel. HDL promotes endothelial function through vasodilator effects of the PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase)/Akt (serine/ threonine kinase 1)/eNOS (endothelial NO synthase)/NO pathway, triggered by some of its components acting on this interface. Indeed, the stimulation of the survival Akt pathway signaling by HDL enhances NO synthesis and inhibiting caspases. Interestingly, HDL-mediated survival effects on the endothelial cells depend on the S1P (sphingosine-1-phosphate)-driven intracellular signaling via S1P1 and S1P3 receptors. Similarly, Apo (apolipoprotein) A-I also seems to have a central role in the NO-induced protective action of HDL through cellular receptors such as SR-BI (scavenger receptor class B member 1). However, HDL from unhealthy patients becomes dysfunctional independently of plasma HDL levels, but through a compositional remodeling involving triglyceride (TG) and SAA (serum amyloid A) enrichment, besides that increased content of Apo C-III and decreased content of Apo A-I, which results in impaired eNOS signaling. Although traditionally the HDL-S1P content of patients with stable coronary artery disease (CAD) is reduced, HDL-bound plasma S1P and S1P elevate within the first 12 h from the event and then fall to similar levels of stable CAD. LBP indicates lipopolysaccharide-binding protein; and LOX, lectin-like oxidized LDL receptor 1. Downloaded from http://ahajournals.org by on April 2, 2020 ulin-activated protein kinase). 88 This event primes phosphorylation of AMPK, which stimulates glucose uptake by translocating GLUT4 (glucose transporter 4) from the sarcolemma to the cell membrane ( Figure 3 ). 88 Consistently, HDL plasma concentration is directly associated with the improvement of IS during the first days after MI. 91, 92 The increase in HDL-C obtained through the inhibition of CETP promoted reduction of blood glucose and increase of IS. 93 Recent studies suggest that protective effects of HDL related to its S1P content are impaired in states with impeded insulin signaling. Lower amounts of S1P were found in HDL particles obtained from patients with metabolic syndrome and type 1 and 2 diabetes mellitus, which were also impaired in their ability to protect cardiomyocytes from oxidative stress, activate eNOS, and to suppress TNF-α-dependent NF-κB-mediated inflammatory response in endothelial cells. [94] [95] [96] [97] [98] In addition, HDL/Apo A-I was found to ameliorate β-cell dysfunction by inhibiting stress-induced proapoptotic pathways through S1P signaling 99 and to stimulate insulin secretion both directly, via activation of ABCA1 in pancreatic β-cells, 100 and indirectly by reducing the generation of oxidized LDL. 101 Of note, both Apo A-I and A-II increase insulin production and secretion by a mechanism similarly dependent on ABCA1 and SR-B1 (scavenger receptor class B member 1) transporters. 102 In line with this, the absence of ABCA1 results in intracellular cholesterol accumulation, inflammation, and decreased insulin secretion. 103 In patients with MI, we found a disruption in the reciprocal interaction between IS and secretion, , thus positively modulating complex I activity and inhibiting mitochondrial permeability transition pore (MPTP) opening and glutathione cycle. In parallel, the HDL/Apo A-I/SRBI (scavenger receptor class B type 1) axis triggers the PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase)/Akt (serine/ threonine kinase 1) pathway, which concurs in stimulation of HKII (hexokinase II) and inhibition of GSK (inosine/guanosine kinase) 3β, ultimately inhibiting the opening of MPTP. Moreover, HDL/Apo A-I binds to the ABCA1 (ATP-binding cassette transporter A1) receptor, prompting an increase of intracellular calcium content, which positively stimulated the CAMKK (calcium/calmodulin-activated protein kinase) with positive effects over AMPK (AMP-activated protein kinase). This pathway ultimately contributes to glycolysis, fueling glucose oxidation. GLUT4 indicates glucose transporter 4. suggesting an upregulation in insulin secretion that was more accentuated among individuals with high HDL-C. 91 
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HDL AND MYOCARDIAL REPERFUSION
It is abundantly clear that coronary blood flow after reperfusion therapy is a critical factor in infarct size, ventricular function, and, subsequently, mortality. 104 In addition, endothelial integrity is essential to prevent new thromboses, attenuate inflammation, and favor the dynamic accommodation of the diameters of the coronary artery lumen and microcirculation so that the blood flow is compatible with the change in the myocardial demand. 104 NO production plays a central role in each of these mechanisms. Unlike normal HDL, post-MI HDL, however, activates LOX-1, thereby inhibiting the activating phosphorylation of Ser1177 and stimulating inhibitory phosphorylation in Thr495 of the eNOS. 57 Indeed, the greater the inflammatory activity after MI and the higher the HDL levels, the greater will be the degree of HDL-mediated inactivation of eNOS. 69 In line with this, plasma NO bioavailability and flow mediated vasodilation decrease after MI more intensively among individuals with higher plasma concentration of HDL than in their counterparts. 5 In both in vitro and ex vivo animal models, HDL stimulates endothelial cells to produce prostacyclin, by increasing arachidonate supply and cyclooxygenase-2 expression. 105 Furthermore, plasma levels of HDL-C are reported to be positively correlated to stable metabolite of prostacyclin 6-keto PGF1a (prostaglandin F1a). 106, 107 Besides favoring vasodilation, HDL inhibits the synthesis of thromboxane A2-a potent vasoconstrictor-by endothelial cells. 105 Interestingly, while large HDL particles are more effective than smaller ones in modulating the prostacyclin/TxA2 (thromboxane A2) balance, 108 delipidated HDL continues to have a residual effect on the stimulation of prostacyclin production. 109 It is likely then that both lipid and protein moieties of HDL have a role in this effect.
In contrast to healthy HDL, post-MI HDL stimulates production of PAI-1 (plasminogen activator inhibitor type 1), and it loses the ability to suppress TF (tissue factor) and to increase TF pathway inhibitor and tPA (tissuetype plasminogen activator). 110 Both native HDL and rHDL can inhibit the endothelial production of adhesion molecules, thus inhibiting neutrophil binding and transmigration through the arterial wall. 51 In contrast, proinflammatory changes in HDL, such as those observed during MI, favor activation of NF-κB and endothelial inflammation. 111 Consistently, post-MI HDL loses its antiapoptotic activity and may even promote endothelial apoptosis through p38-MAPK-mediated activation of the proapoptotic Bcl-2 (B-cell lymphoma protein 2) protein tBid (proapoptotic truncated BID). 28, 57, 110 Superficial erosion after endothelial cell apoptosis favors thrombi formation.
Unlike cardiomyocytes, endothelial cells are resistant to ischemia and are functional even after 4 to 6 hours of oxygen deprivation. Endothelial compensatory cellular mechanisms occur to enhance protective PI3Kα/Akt/ eNOS signaling and angiogenesis, attenuating myocardial ischemic injury in vivo. 112 Additionally, more cardiac microcirculation endothelial cell survival via activation of AMPKα by melatonin could also promote endothelial barrier function, eNOS contents, and finally restrain infarcted area. 113 On the contrary, endothelial cells are actually more sensitive to the reperfusion process. 114 The mechanisms by which HDL may attenuate this effect are similar in endothelial cells and cardiomyocytes and will be discussed in detail below.
HDL AND I/R INJURY IN ENDOTHELIAL CELLS AND CARDIOMYOCYTES
A growing body of evidence supports the notion that HDL may reduce apoptosis of endothelial cells and cardiomyocytes induced by I/R injury. 46 Prevention of the opening of the mitochondrial permeability transition pore by reperfusion with HDL indicates its potential as an ischemic postconditioning provider. 115 In murine models, intravenous infusion of Apo A-I activates both reperfusion injury signaling kinase and survivor activating factor enhancement (SAFE) pathways, thus reducing apoptosis. 116 HDL activation of both TNF-α and STAT3 is required to trigger the SAFE pathway 117,118 -a preconditioning and postconditioning effect that is mitigated in TNF-α knockout mice and in STAT3 knockout cardiomyocytes. 119 Moreover, evidences also suggest that SAFE signaling is conditioned to the activation of the S1P cascade by the HDL/S1P complex: (1) intracellular S1P is able to regulate the SAFE pathway triggered by TNF-α 120 ; (2) S1P requires the presence of TNF signaling to protect against I/R injury 118, 121 ; (3) SAFE pathway is activated by HDL, S1P, S1P mimetic FTY720, 122 or rHDL through S1P2 receptor 123 ; and (4) STAT3-deficient animals lose this protective capacity induced by S1P. 118, 121 Furthermore, Akt and ERK signaling is also downstream of the activation of the S1P receptors 124, 125 and is involved in the reperfusion injury signaling kinase pathway, whose activation also favors ischemic postconditioning. 126 HDL-S1P is able to activate STAT3 in 2 different residues: serine 727 and tyrosine 705. P-ser-727 translocates to the mitochondrial space after its interaction with death modulation protein GRIM19 (retinoid interferoninduced mortality 19)-a component of complex I in the electron transport chain-and assembles to mitochondrial complex I. 127 The mitochondrial effects of STAT3 may be summarized as follows: (1) it preserves mitochondrial integrity, (2) inhibits mitochondrial permeability transition pore opening, and (3) favors ATP production. 128 This leads to a fast, nontranscriptional, and still not fully comprehended STAT3-mediated signaling in postconditioning. 129, 130 In parallel, p-tyrosine 705-STAT3 is translocated to nucleus by importin α5, binds to gammainterferon-activation, site and endorses the synthesis of 131, 132 It is worth mentioning, however, that more than an hour is required to phosphorylate STAT3 at tyrosine 705 residue activating the SAFE transcriptional pathway 123 and ≈24 hours to produce the proteins required for this protective action. 132 Thus, the postconditioning effect of HDL can be categorized as an early effect that usually starts in the first minutes of reperfusion and is based on a mitochondrial interaction via STAT3 and a late effect based on transcriptional signaling at least partially mediated by STAT3 phosphorylation.
The HDL activation of the reperfusion injury signaling kinase pathway may also occur via SR-BI (scavenger receptor class B member 1) interaction and may protect myocardium in a mitochondrial manner (Figure 3 ). In fact, Akt desensitizes mitochondrial permeability transition pore by interacting with hexoquinase II and GSK (inosine/guanosine kinase)-3β and inhibits apoptosis by suppressing proapoptotic proteins, such as caspase 9. 133, 134 In parallel, ERK stimulates antiapoptotic protein Bcl2 135 and desensitizes mitochondrial permeabil-ity transition pore through GSK3β and cyclophilin D. 136 This results in myocardial salvage, as demonstrated by worsened ischemic injury in ERK2 +/− mice and by experiments with Akt inhibitors. 137 Reperfusion injury is partially attributable to cellular swelling and membrane rupture that succeeds opening of hemichannels in cardiomyocytes. The permeability of these channels is modulated by the phosphorylation status of its main protein, Cx43 (connexin 43), which is a gap junction channel present in cardiomyocytes that may also mediate cardioprotection by HDL. 138, 139 Infusion of healthy HDL or S1P during the first minutes of reperfusion leads to phosphorylation of Cx43 serine 368 residue. 140 Of note, applying this protocol to mice with nonphosphorylatable mutations of serine 368 or in the presence of S1P2 and S1P3 inhibitors deeply impairs HDL/S1P conditioning. 140 Moreover, activation of PKC by HDL is plausibly the link between this particle and its downstream effects over Cx43. 141 These data support that myocardial salvage by HDL is partially explained by its interaction with Cx43, which is mediated by S1P receptors and modulated by PKC activation. A summary of the HDL-mediated effects on cardiomyocytes and endothelial cells during I/R injury is shown in Table 2 . Table 2 
. Summary of the Reported Effects Obtained by Healthy HDL Interaction With Endothelial Cells and Cardiomyocytes in Myocardial Infarction Models
Outcomes
Inducing mechanisms References
Effects on endothelial cells
Apo M-containing HDL Promotes endothelial homeostasis, such as barrier functions and ERK signaling Activating G-proteincoupled S1P receptors
47
Recombinant soluble Apo M S1P-bound Apo M-Fc activating endothelial cells and barrier functions Activating S1P1 receptor 48 HDL-bound S1P Inhibits endothelial inflammation through interaction of S1P1 receptor with β-arrestin to inhibit NF-κB activation or enhancing PI3K/AKT/eNOS signaling Activating S1P1 receptor inhibits NF-κB signaling 58,60,61
Activation of Sphk2 S1P receptors promoted transactivation of PKC/ERK followed by Sphk2 phosphorylation COX-2 expression and PGI-2 release 64
Effects on cardiomyocytes
Recombinant soluble Apo M Its protective effect on the endothelium attenuates myocardial I/R Activating S1P1 receptor 48
Sphk1 activity Ischemic postconditioning promotes S1P release after increased Sphk1 activity Activating S1P receptors 53-55 S1P agonist treatment eNOS-dependent arterial vasodilatation S1P3 receptor 56 S1P-rich HDL Reduced infarct size S1P3 receptor 57 HDL native/S1P and reconstituted S1Penriched HDL Activates STAT3 to promote cardiomyocyte survival and inhibit apoptosis. Also, inhibits macrophage apoptosis S1P2/3 receptors/ERK 65,143
Postconditioning effect of S1P-rich HDL TNF-α and STAT3 are required to activate this protective pathway, which preserves mitochondrial integrity and protects against I/R injury SAFE pathway triggered by S1P2 receptor. 117,125,129,143 S1P Cross talk between SAFE and RISK at the onset of the reperfusion protects myocardial I/R RISK pathway-PI3K-Akt and ERK 1/2 prosurvival kinases triggered by S1P receptors 117 HDL/S1P conditioning Reduced myocardial I/R through phosphorylation of the gap junction protein Cx43 S1P2/3 receptors 137-140
AKT indicates serine/threonine kinase 1; Apo, apolipoprotein; COX-2, cyclooxygenase 2; Cx43, connexin 43; eNOS, endothelial NO synthase; ERK, extracellularregulated kinase; HDL, high-density lipoprotein; NF-κB, nuclear factor-κB; PGI-2, prostacyclin; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; PKC, protein kinase C; RISK, reperfusion injury signaling kinase; S1P, sphingosine-1-phosphate; SAFE, survivor activating factor enhancement; Sphk1, sphingosine kinase 1; Sphk2, sphingosine kinase 2; STAT3, signal transducer and activator of transcription 3; and TNF, tumor necrosis factor.
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